Novartis (NYSE:NVS) Shares Gap Up - Still a Buy?

Key Points

• Novartis shares jumped from a $152.06 close to a $162.15 open after remibrutinib met the primary endpoints in two Phase III multiple sclerosis trials, improving the drug’s prospects as a future growth product.
• Investor sentiment remains mixed: analysts collectively rate the stock “Hold,” with an average price target of $141.20, below its latest trading price near $161.64.
• Pipeline risks persist after Novartis paused eight rap-cel autoimmune cell-therapy studies following three patient deaths, raising safety concerns despite the positive remibrutinib results.

Novartis AG (NYSE:NVS - Get Free Report)'s share price gapped up prior to trading on Tuesday . The stock had previously closed at $152.06, but opened at $162.15. Novartis shares last traded at $161.64, with a volume of 1,164,231 shares.

Trending Headlines about Novartis

Here are the key news stories impacting Novartis this week:

• Positive Sentiment: Remibrutinib meets Phase III goals: Novartis said the REMODEL-1 and REMODEL-2 trials met their primary endpoints, with remibrutinib significantly reducing annualized relapse rates versus teriflunomide. The drug also performed favorably on secondary measures, including MRI lesion reductions, and a combined analysis indicated a clinically meaningful delay in disability progression. Novartis plans to present detailed data and seek regulatory approvals globally, strengthening the drug’s potential as a future growth product. Novartis' oral multiple sclerosis drug meets main goal in late stage studies
• Positive Sentiment: Large-market opportunity supports investor optimism: The apparent superiority over an established multiple sclerosis treatment, combined with a favorable safety profile, improves the commercial prospects for remibrutinib and provides a positive read-through for Novartis’ pipeline. Novartis Reported Encouraging Trial Data for a Multiple Sclerosis Drug
• Neutral Sentiment: Mixed institutional and options signals: Recent filings show both notable additions and reductions by large investors, while put-option activity was unusually high. These positioning indicators may reflect hedging or heightened volatility rather than a clear change in long-term sentiment.
• Neutral Sentiment: Minor earnings-estimate reduction: Erste Group Bank modestly lowered its FY2027 EPS forecast to $9.80 from $9.82, a change too small to materially alter the investment outlook. Erste Group Bank Forecasts Reduced Earnings for Novartis
• Negative Sentiment: Autoimmune cell-therapy trials paused: Novartis halted eight studies of experimental rap-cel after three patient deaths. The pause creates safety concerns and could delay or reduce the value of this portion of the pipeline, although the impact was overshadowed by the remibrutinib data. Novartis pauses autoimmune cell therapy studies after deaths

Analysts Set New Price Targets

NVS has been the topic of several research analyst reports. Citigroup restated a "buy" rating on shares of Novartis in a research report on Wednesday, July 22nd. Weiss Ratings reiterated a "buy (b)" rating on shares of Novartis in a research report on Friday, July 24th. Seven research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, Novartis presently has an average rating of "Hold" and an average target price of $141.20.

Novartis Stock Performance

The company has a market capitalization of $307.41 billion, a P/E ratio of 24.31, a price-to-earnings-growth ratio of 2.64 and a beta of 0.45. The business has a 50 day moving average of $155.14 and a 200 day moving average of $153.72. The company has a quick ratio of 0.67, a current ratio of 0.86 and a debt-to-equity ratio of 0.89.

Novartis (NYSE:NVS - Get Free Report) last released its quarterly earnings data on Tuesday, June 30th. The company reported $2.41 earnings per share (EPS) for the quarter. The business had revenue of $14.95 billion for the quarter. Novartis had a return on equity of 38.56% and a net margin of 23.29%. On average, sell-side analysts predict that Novartis AG will post 8.84 earnings per share for the current year.

Institutional Investors Weigh In On Novartis

Several large investors have recently bought and sold shares of NVS. J.W. Cole Advisors Inc. grew its stake in shares of Novartis by 0.6% in the 4th quarter. J.W. Cole Advisors Inc. now owns 10,577 shares of the company's stock worth $1,348,000 after buying an additional 64 shares in the last quarter. Roundview Capital LLC raised its position in Novartis by 2.5% during the fourth quarter. Roundview Capital LLC now owns 2,711 shares of the company's stock valued at $374,000 after purchasing an additional 66 shares during the period. CPC Advisors LLC lifted its stake in shares of Novartis by 4.6% in the 2nd quarter. CPC Advisors LLC now owns 1,516 shares of the company's stock valued at $238,000 after purchasing an additional 66 shares during the last quarter. IMA Advisory Services Inc. boosted its holdings in shares of Novartis by 10.9% in the 4th quarter. IMA Advisory Services Inc. now owns 710 shares of the company's stock worth $98,000 after purchasing an additional 70 shares during the period. Finally, Moody National Bank Trust Division increased its position in shares of Novartis by 4.2% during the 2nd quarter. Moody National Bank Trust Division now owns 1,802 shares of the company's stock valued at $282,000 after purchasing an additional 72 shares during the last quarter. Institutional investors own 13.12% of the company's stock.

About Novartis

Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.

The company's activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source